Predictors for starting depot administration of risperidone in chronic users of antipsychotics

Journal of Clinical Psychopharmacology

Volumn 28, Issue 6, 2008, Pages 625-630

  Vehof, Jelle ^a   Postma, Maarten J ^a   Bruggeman, Richard ^a   De Jong Van Den Berg, Lolkje T W ^a   Van Den Berg, Paul B ^a   Stolk, Ronald P ^a   Burger, Huibert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMPERIDOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; EXTRAPYRAMIDAL SYNDROME; INJECTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT REFERRAL; PATIENT SELECTION; PHARMACY; RISK; SEX DIFFERENCE; STATISTICS;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; CHRONIC DISEASE; COMMUNITY PHARMACY SERVICES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INJECTIONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PATIENT SELECTION; REFERRAL AND CONSULTATION; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS;

EID: 59049102655     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818a6d10     Document Type: Article

References (28)

1. Mc Grath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the in?uence of schizophrenia: the distribution of rates and the in?uence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13.
2. Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997;171:509-518.
3. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429.
4. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60:4-6.
5. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279-293.
6. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense [correction appears in Am J Manag Care 1998;4:611].
7. Am J Manag Care. 1998;4:369-383.
8. Schultz SH, North SW, Clevelands GS, et al. Schizophrenia: a review. Am Fam Physician. 2007;75:1821-1829.
9. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
10. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
11. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222.
12. Davis JM, Matalon L, Watanbe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47:741-773.
13. Weiden P, Glazer W. Assessment and treatment selection for Frevolving door' inpatients with schizophrenia. Psychiatr Q. 1997;68:377-392.
14. Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs. 1996;6:367-381.
15. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53:426-433
16. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry. 1993;54:24-30.
17. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 1998;8:55-66.
18. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 2004;161:1-56.
19. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005; 23:75-89.
20. Heeg BM, van Aalst G, van den Arend U, et al. A discrete events model of long term outcomes and costs of treatment with long-acting risperidone in schizophrenia [abstract no. PMH5]. Value Health. 2002;5:515-516. Poster also presented at the International Society for Pharmacoeconomics and Outcomes Research 5th Annual European Congress; November 3-5, 2002; Rotterdam, the Netherlands.
21. Rijcken CA, Boelema GJ, Slooff CJ, et al. Off-label use of antipsychotics in the community pharmacy: the sex differences. Pharmacopsychiatry. 2003;36:187-191.
22. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat. 2005;11:203-213.
23. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
24. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking ?rst-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58:482-488.
25. Niaz OS, Haddad PM. Thirty-?ve months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116: 36-46.
26. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10:577-581.
27. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67: 1948-1953.
28. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300-307.